Subject(s)
Esophageal Neoplasms , Melanoma , Deglutition Disorders/etiology , Deglutition Disorders/physiopathology , Disease Progression , Endosonography/methods , Esophageal Neoplasms/pathology , Esophageal Neoplasms/physiopathology , Esophageal Neoplasms/surgery , Esophagectomy/adverse effects , Esophagectomy/methods , Fatal Outcome , Humans , Male , Melanoma/pathology , Melanoma/physiopathology , Melanoma/surgery , Middle Aged , Neoadjuvant Therapy/methods , Neoplasm Staging , Reoperation/adverse effects , Reoperation/methodsABSTRACT
Malignant peritoneal effusions often arise in patients with ovarian carcinoma. They are a hazardous complication of cancer. Systematic intraperitoneal chemotherapy is not necessarily followed by long-term remission and may even induce untoward side effects. Intraperitoneal interleukin-2 (IL-2) and IL-2/lymphokine-activated killers (LAK) biotherapy showed high efficacy in treatment of ovarian carcinoma patients suffering from peritoneal effusions. The objective effect was 80.1% and 82.6%, respectively. Our results suggest that intraperitoneal biotherapy may be extended to dealing with malignant peritoneal effusions in ovarian carcinoma.
Subject(s)
Antineoplastic Agents/administration & dosage , Ascitic Fluid/drug effects , Biological Therapy/methods , Interleukin-2/administration & dosage , Killer Cells, Lymphokine-Activated , Neoplasms, Glandular and Epithelial/therapy , Ovarian Neoplasms/therapy , Adult , Aged , Ascitic Fluid/pathology , Carcinoma, Ovarian Epithelial , Female , Humans , Infusions, Parenteral , Middle Aged , Neoplasms, Glandular and Epithelial/drug therapy , Neoplasms, Glandular and Epithelial/pathology , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/pathology , Treatment OutcomeABSTRACT
We studied the possibility of using coal hemosorbents for elimination gram-positive and gram-negative microorganisms from the blood. After hemosorption, the number of S. aureus and K. pneumoniae pneumoniae colony-forming units significantly decreased. The obtained results indicate that coal sorbents can bind and probably eliminate gram-positive and gram-negative bacteria from the blood.
Subject(s)
Coal , Hemofiltration/methods , Klebsiella pneumoniae/isolation & purification , Staphylococcus aureus/isolation & purification , Bacteremia/blood , Bacteremia/microbiology , Bacteremia/therapy , Humans , Klebsiella pneumoniae/growth & development , Staphylococcus aureus/growth & developmentABSTRACT
Clinical efficiency of low dose Roncoleukin was studied in 30 patients with metastatic exudative pleurisy. Intrapleural therapy proved to be highly effective (overall effect reached 84%), was well tolerated, and improved patients' quality of life.
Subject(s)
Interleukin-2/therapeutic use , Neoplasms , Pleurisy , Adult , Aged , Female , Humans , Immunophenotyping , Injections, Intralesional , Interleukin-2/administration & dosage , Male , Middle Aged , Neoplasms/complications , Neoplasms/pathology , Pleurisy/drug therapy , Pleurisy/etiology , Treatment OutcomeABSTRACT
To analyze the functions of lymphokine-activated killer cells (LAKC) and to study their phenotype are of paramount importance in the assessment of their role in antitumor immunity. The natural killers--hepatic T cells--have been shown to be used to prepare LAKS that have a higher cytotoxic activity than LAKS that are generalized from peripheral mononuclear cells.
Subject(s)
Killer Cells, Lymphokine-Activated/immunology , Killer Cells, Natural/immunology , Liver Neoplasms/immunology , Adolescent , Adult , Aged , Antigens, CD/blood , Culture Media , Cytotoxicity Tests, Immunologic , Cytotoxicity, Immunologic , Data Interpretation, Statistical , Humans , Immunophenotyping , Immunotherapy, Adoptive , Interleukin-2/immunology , Leukocytes, Mononuclear/immunology , Liver/immunology , Liver Neoplasms/blood , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Middle Aged , Phenotype , T-Lymphocytes/immunology , Tumor Cells, CulturedABSTRACT
Although there has been a sufficiently steady trend towards a decrease in the incidence of carcinoma of the stomach (CS), the problem related with treatment of this malignant tumor remains acute up to now in many countries. Presently, the surgical method, i.e. gastrectomy in the volume of D2 (with splenectomy being an element of it) remains the basic treatment for CS of stages I-III. A removal of an essential portion of the lymphoid tissues brings about a pronounced, prolonged and hard-to-correct immunodeficiency, which, in its turn, aggravates the risk of postoperative infectious complications and cuts the relapse-free life period. The method, offered by us, makes it possible to obtain the lymphocine-activated cells from the mononuclear cell population of the spleen, removed in operation, and to use them in the adoptive immunotherapy for the purpose of improving the life duration and quality for this category of patients. However, elaboration of methods combining the activation of both non-specific and specific anti-tumor immunity through designing the anti-tumor auto-vaccines based on dendrite cells is the most promising direction in the adoptive immunotherapy for a radically operated CS.
